Skip to main content
. 2014 Apr;88(8):4558–4571. doi: 10.1128/JVI.03431-13

TABLE 2.

Summary of α2β1, GM1, and N-acylneuraminic acid usage for cell binding and/or infection by sialidase-sensitive (animal) rotaviruses

Virus strain α2β1 usagea Untreated cells
Sialidase-treated cells
Infectivity reduced by CTBb Proposed internalization pathwayc Reduced by Neu5Acα2Me (% at 10 mM)
Reduced by Neu5Gcα2Me (% at 10 mM)
Infectivity reduced by a-GM1d Effect of sialidase on given property
Infectivity reduced by Neu5Acα2Me Infectivity reduced by Neu5Gcα2Med
VP8* boundd Infectivity VP8* boundd Infect VP8* boundd Infectivity
TFR-41 + CE ND 19d ND 0d ND ND Reducedd d
CRW-8 ND 41 46e 43 66e ND ND Reducede,f f ND
RRV + Non-CE ND 60g ND 40e ND Reducedh d ND
NCDV + ND 34 29e 41 41e ND Reduced Reducedi d +
a

Shown in references 8, 15, 18, 32, and 35. In this study, the extent of α2β1 usage was shown not to be affected by sialidase treatment of cells.

b

Shown by CTB infectivity inhibition in this study for UK, TFR-41, and NCDV and in references 7 and 31 for CRW-8 and RRV. STD NMR analysis showed minimal RRV VP8* binding to a-GM1 (this study).

c

Data are from references 11 and 13. CE, clathrin-mediated endocytosis; Non-CE, endocytosis independent of clathrin and caveolin; ND, not determined.

d

Shown in this study.

e

Shown in this study and reference 38.

f

Shown in this study and reference 31.

g

Blockade shown in this study and references 37, 38, and 67.

h

Shown in this study and references 27, 34, and 36.

i

Shown in this study and references 27 and 29.

HHS Vulnerability Disclosure